13 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 13 of 13 clinical reviews.
A physician-reviewed guide to off-label tirzepatide (Mounjaro) use in adolescents aged 12 to 17, covering the current evidence base, dosing considerations, approved alternatives, and what families should ask before starting treatment.
Evidence-based guidance on starting, adjusting, and monitoring tirzepatide (Mounjaro) in geriatric patients transitioning from pediatric or general adult care to age-specific protocols, including dose modifications, safety considerations, and clinical outcomes data.
A clinician-reviewed guide to tirzepatide (Mounjaro) use in patients aged 65 and older, covering efficacy, safety, dosing, muscle preservation, and guideline recommendations for geriatric populations.
A clinical guide to using Mounjaro (tirzepatide) off-label in geriatric patients aged 65+, covering efficacy data, dose titration, sarcopenia risk, renal considerations, and prescriber decision frameworks.
A clinician-reviewed guide for caregivers administering Mounjaro (tirzepatide) to pediatric patients under age 12, covering dosing, injection technique, storage, safety monitoring, and when to call the prescriber.
Tirzepatide is not approved for children under 12. Learn what the evidence shows about developmental safety, growth, puberty, and metabolic effects in young pediatric patients.
A clinical guide to managing Mounjaro (tirzepatide) use in children under 12, covering school accommodations, physical activity safety, hypoglycemia protocols, and what parents and school nurses need to know.
Tirzepatide (Mounjaro) is not approved for children under 12. This clinical guide covers the evidence gap, off-label risk framework, current pediatric obesity guidelines, and what families should ask their physician.
Tirzepatide is not FDA-approved for children under 12. Learn what the evidence says about pediatric obesity management, why transition planning matters, and how care teams bridge the gap as young patients move toward adult GLP-1 protocols.
A clinical guide to transitioning adolescents aged 12-17 on tirzepatide (Mounjaro) to adult obesity and metabolic care, covering dose continuity, monitoring, consent, and what the evidence says.
A clinician-reviewed guide to managing tirzepatide (Mounjaro) in adolescents aged 12-17, covering school schedules, injection timing, physical activity, nutrition during sports, and how to communicate with teachers and coaches.
A clinician-reviewed guide to tirzepatide (Mounjaro) use in geriatric patients, covering physical activity, fall risk, muscle preservation, nutrition, and how older adults can safely stay active while on this GLP-1/GIP medication.
Step-by-step caregiver guidance for administering Mounjaro (tirzepatide) to adults aged 65 and older, including dose escalation, injection technique, hypoglycemia monitoring, and age-specific safety considerations.